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Abstract
Background: Fibroadenoma (FA) is the most common benign solid breast mass in women, with no definite
method of management. Because fibroadenoma is dependent on female sex hormones and comprises
hypertrophic changes at cellular levels, we investigated the effects of metformin (MF), a safe hypoglycemic agent
with anti-estrogenic and anti-proliferative properties, in the management of fibroadenoma.
Methods: In this randomized clinical trial study, eligible women with fibroadenomas were assigned randomly to
the metformin (1000 mg daily for six months) or the placebo group. Breast physical and ultrasound exam was
performed before and after the intervention, and the changes in the size of fibroadenomas were compared in the
two groups.
Results: Overall, 83 patients in the treatment, and 92 in the placebo group completed the study. A statistically
significant difference in changing size between the two groups was observed only in the smallest mass. In the
largest FAs, the rate of size reduction was higher in the treatment group (60.2 % vs. 43.5 %); while a higher rate of
enlargement was observed in the placebo group (38 % vs. 20.5 %). In the smallest FAs, the rate of the masses that
got smaller or remained stable was about 90 % in the treatment group and 50 % in the placebo group. We
categorized size changes of FAs into < 20 % enlargement and ≥ 20 % enlargement. The odds ratio (OR) for an
elargemnt less than 20% was 1.48 (95 % CI = 1.10–1.99) in the treatment group in comparison with the placebo
group; the odds for an enlargement less than 20% was higher in women with multiples fibroadenomas (OR = 4.67,
95 % CI: 1.34–16.28). In our study, no serious adverse effect was recorded, and the medicine was well-tolerated by
all users.
Conclusions: This is the first study that evaluates the effect of MF on the management of fibroadenoma, and the
results suggest a favorable effect. Larger studies using higher doses of MF and including a separate design for
patients with single or multiple FAs are suggested in order to confirm this effect.
Trial registration: This trial (IRCT20100706004329N7) was retrospectively registered on 2018-10-07.
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